Thermo Fisher Scientific (TMO) Receivables - Other (2018 - 2026)

Thermo Fisher Scientific (TMO) has reported Receivables - Other for 9 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other rose 17.14% year-over-year to $1.7 billion; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 17.14% YoY), and the FY2025 full-year result was $1.7 billion, up 16.1% from the prior year.
• Receivables - Other held at $1.7 billion in Q2 2026 per TMO's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Receivables - Other topped out at $1.7 billion in Q2 2026 and bottomed at $1.1 billion in Q2 2022.
• Historically, Receivables - Other has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other jumped 54.46% in 2022, then slipped 3.94% in 2025.
• Over 5 years, Receivables - Other stood at $1.3 billion in 2022, then grew by 9.98% to $1.4 billion in 2023, then decreased by 0.55% to $1.4 billion in 2024, then climbed by 16.1% to $1.7 billion in 2025, then climbed by 1.32% to $1.7 billion in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.7 billion, $1.7 billion, and $1.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.